The stage of preclinical AD precedes MCI and encompasses the spectrum of presymptomatic autosomal dominant mutation carriers, asymptomatic biomarker-positive older individuals at risk for progression to MCI that is due to AD and AD dementia, as well as biomarker-positive individuals who have demonstrated a subtle decline from their own baseline that exceeds the expected in typical aging but would not yet meet criteria for MCI [6]. aColumbia University Medical Center, New York, New York. bUT Southwestern Medical Center, Dallas, Texas. cResearch Author, Emory University, Atlanta, Georgia. dPanel Chair, Montefiore Medical Center, Bronx, New York. eUC San Diego Health, San Diego, California. fOttawa Hospital Research Institute and the Department of Radiology, The University of Ottawa, Ottawa, Ontario, Canada; Canadian Association of Radiologists. gMCVH-Virginia Commonwealth University, Richmond, Virginia; Neurosurgery Expert. hUniversity of Kansas Medical Center, Kansas City, Kansas. iEinstein Healthcare Network, Philadelphia, Pennsylvania. jUniversity of California San Diego Medical Center, San Diego, California. kOregon Health & Science University, Portland, Oregon. lUniversity of North Carolina School of Medicine, Chapel Hill, North Carolina; American Academy of Neurology. mSheppard Pratt Health System, Towson, Maryland; American Psychiatric Association. nNorthwestern University Feinberg School of Medicine, Chicago, Illinois; Neurosurgery Expert. oWalter Reed National Military Medical Center, Bethesda, Maryland. pColumbia University Medical Center, New York, New York. qSpecialty Chair, Atlanta VA Health Care System and Emory University, Atlanta, Georgia. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels.
Dementia. The stage of preclinical AD precedes MCI and encompasses the spectrum of presymptomatic autosomal dominant mutation carriers, asymptomatic biomarker-positive older individuals at risk for progression to MCI that is due to AD and AD dementia, as well as biomarker-positive individuals who have demonstrated a subtle decline from their own baseline that exceeds the expected in typical aging but would not yet meet criteria for MCI [6]. aColumbia University Medical Center, New York, New York. bUT Southwestern Medical Center, Dallas, Texas. cResearch Author, Emory University, Atlanta, Georgia. dPanel Chair, Montefiore Medical Center, Bronx, New York. eUC San Diego Health, San Diego, California. fOttawa Hospital Research Institute and the Department of Radiology, The University of Ottawa, Ottawa, Ontario, Canada; Canadian Association of Radiologists. gMCVH-Virginia Commonwealth University, Richmond, Virginia; Neurosurgery Expert. hUniversity of Kansas Medical Center, Kansas City, Kansas. iEinstein Healthcare Network, Philadelphia, Pennsylvania. jUniversity of California San Diego Medical Center, San Diego, California. kOregon Health & Science University, Portland, Oregon. lUniversity of North Carolina School of Medicine, Chapel Hill, North Carolina; American Academy of Neurology. mSheppard Pratt Health System, Towson, Maryland; American Psychiatric Association. nNorthwestern University Feinberg School of Medicine, Chicago, Illinois; Neurosurgery Expert. oWalter Reed National Military Medical Center, Bethesda, Maryland. pColumbia University Medical Center, New York, New York. qSpecialty Chair, Atlanta VA Health Care System and Emory University, Atlanta, Georgia. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels.